Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Epilepsia. 2021 Oct 7;62(12):3091–3104. doi: 10.1111/epi.17090

Figure 5. OV329 reduces seizure and afterdischarge durations in amygdala-kindled rats.

Figure 5

Effects of 30 and 40 mg/kg OV329 injected intraperitoneally on the duration of motor seizures (seizure duration 1, SD1; A, B) and the time of motor seizures plus the adjacent time of immobility (seizure duration 2, SD2; C, D) at the afterdischarge threshold (ADT) and the generalized seizure threshold (GST), and on the afterdischarge durations ADD1 (E, F) and ADD2 (G, H) in rats (n = 6). Saline (S) injections served as pre- and post-drug controls. At 40 mg/kg OV329, none of the animals expressed generalized motor seizures and the SD and ADD at GST were set at 0 s (B, D, F, G) for data evaluation. Data are expressed as mean+SEM. Statistically significant differences between OV329 and saline as pre-drug control are indicated by asterisks, and differences between OV329 and saline as post-drug control are indicated by hashtags (one-way mixed-effects model analysis, post-hoc Sidak correction, *P<0.05, **, ##P<0.01, ***, ###P<0.001, ****P<0.0001).